Global EditionASIA 中文雙語Fran?ais
    World
    Home / World / Americas

    US: AstraZeneca results may have included outdated info

    Updated: 2021-03-24 04:06
    Share
    Share - WeChat
    [Photo/Agencies]

    WASHINGTON — AstraZeneca may have included “outdated information” in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusual public rift that could further erode confidence in the shot.

    In response, AstraZeneca said that it is working on more up-to-date information and that the more recent findings are consistent with the earlier ones. It promised an update within 48 hours.

    It was not clear exactly what concerns U.S. health officials have. But the unprecedented tension erupted just hours after AstraZeneca released information it hoped would help settle lingering questions about the effectiveness of a vaccine that is being widely used in Europe and other parts of the world and is about to be considered for use in the U.S.

    The company announced on Monday that a predominantly U.S. study of 32,000 volunteers showed its vaccine was 79% effective in preventing symptomatic COVID-19 disease. It also stressed there were no severe illnesses or hospitalizations among volunteers given the vaccine, compared with five cases among those given dummy shots.

    But shortly after midnight, the National Institutes of Health issued a statement saying the independent monitors that oversee the study had “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.” The NIH urged the company to “ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.” Outside experts were surprised and puzzled by the spat. But they noted that ultimately the Food and Drug Administration will scrutinize all the data before deciding whether AstraZeneca's vaccine can be rolled out in the U.S. “It would seem that whatever this communication misstep is, at the end of the day the data will have to stand for itself,” said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief.

    The NIH's Dr. Anthony Fauci told ABC's “Good Morning America” that the incident “really is what you call an unforced error" and that he expects the discrepancy to be straightened out.

    Fauci also said the episode shows the U.S. regulatory system is working: “The data and safety monitoring board picking up this discrepancy was an example of a safeguard.” But that nitty-gritty seldom is seen by the public, something now exposed by the extraordinary microscope being applied to development of the world's COVID-19 vaccines.

    Every vaccine trial is overseen by a “data and safety monitoring board,” or DSMB. These boards include scientists and statisticians who are experts in their fields but have no ties to either the government or the vaccine makers.

    In the AstraZeneca study, just like studies of the other vaccines in use, some participants get the real vaccine and the rest get dummy shots, and neither they nor their doctors know which is which. Only the DSMB has the power to unlock the code of who got which and peek at how the volunteers are faring before a study is finished.

    The DSMB watches for safety concerns and also deems when the study has met pre-determined endpoints showing it's time for an effectiveness calculation. It was the NIH-appointed DSMB that raised the concerns about AstraZeneca's data.

    On Tuesday, AstraZeneca said that the data it first released included COVID-19 cases that occurred up to Feb. 17, as the study rules specified, and that it is continuing to analyze cases that have occurred since then. It said a preliminary analysis of more recent data was consistent with what it had already reported.

    It is common for companies developing COVID-19 vaccines to release early data and to continue studying results as they come in. Some experts had hoped that Monday's AstraZeneca announcement would help rebuild public confidence in the shot around the world.

    The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then last week a scare about blood clots that had some countries temporarily pausing inoculations.

    The U.S. study findings announced by AstraZeneca were consistent with studies from elsewhere — and real-world use in Britain — that found the vaccine offers good protection against the worst COVID-19 has to offer. But company executives refused repeated requests from reporters to provide a breakdown of the 141 COVID-19 cases it was using to make the case for the shot's effectiveness.

    The company has said it aims to file an application with the FDA in the coming weeks.

    Agencies via Xinhua

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    久久久久亚洲av成人无码电影| 午夜视频在线观看www中文| 日韩中文字幕在线观看| 无码137片内射在线影院| 暖暖日本免费中文字幕| 东京热无码av一区二区| 亚洲中文字幕无码不卡电影| 亚洲va中文字幕无码久久不卡 | 亚洲日产无码中文字幕| 精品成在人线AV无码免费看| 国产激情无码一区二区三区 | 久久久这里有精品中文字幕| 亚洲国产av无码精品| 日韩精品无码熟人妻视频| 无码区日韩特区永久免费系列 | 狠狠综合久久综合中文88| 四虎国产精品永久在线无码 | 久久精品国产亚洲AV无码偷窥| 熟妇人妻系列av无码一区二区| 日本中文字幕中出在线| 中文字幕无码不卡免费视频| 久久久久亚洲?V成人无码| 国产精品热久久无码av| JLZZJLZZ亚洲乱熟无码| 国产白丝无码免费视频| 久久久久亚洲av无码专区导航| 无码欧精品亚洲日韩一区| 亚洲色中文字幕无码AV| 亚洲动漫精品无码av天堂| 亚洲色无码一区二区三区| 亚洲国产无套无码av电影| 中文字幕乱码人妻无码久久| 国模无码人体一区二区| 一本加勒比HEZYO无码人妻| 中文有码vs无码人妻| 亚洲AV无码久久精品色欲| 亚洲AV人无码激艳猛片| 久久精品无码一区二区无码| 69ZXX少妇内射无码| 少妇无码太爽了不卡视频在线看| 亚洲国产av无码精品|